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Double filtration plasmapheresis (DFPP) is a recently 
developed apheretic technique used in human medicine 
for several pathological conditions such as metabolic 
(hypercholesterolemia, hyperlipoproteinemia), 
neurologic (myasthenia gravis, polineuropathy, 
Guillam-barrè sindrome), hematologic (thrombotic 
thrombocytopenic purpura), dermatolgic (phemphigus), 
rheumatolgic (systemic lupus erythematosus) and renal 
(acute glomerulonephritis) (Lyu et al., 2002; Yeh et al., 
2006; Fernández-Fuertes et al., 2010; Karakus et al., 
2013; Kasuya et al., 2013; Lumlertgul et al., 2013; 
Li et al., 2015). Compared to plasma exchange (PE), 
DFPP tecnique selectively removes high-molecular 
weight substances, including immunoglobulins (Ig) 
and immune complexes, without the need to infuse 
substitution fluids to the patient (Yeh et al., 2006). In 
human medicine, PE technique has been historically 
used to treat hyperviscosity syndrome (HVS) secondary 
to multiple myeloma (Zarcovic and Kwaan, 2003; 
Ballestri et al., 2007). However, recent acquisitions 
showed that DFPP can be an effective alternative to PE 
in the treatment of HVS (Jiang et al., 2014). HVS is a 
life-threatening complication and can occur when the 
normal plasma viscosity increases as a consequence of 
excessive increase in blood cells or abnormal plasma 
components, such as antibodies, immune complexes, 
para-proteins and cryoglobulins (Zarcovic and Kwaan, 
2003; Ballestri et al., 2007; Dumas et al., 2015). HVS 
is a common finding in Waldenström’s syndrome, 
macroglobulinemia and multiple myeloma (Mehta 
and Singhal, 2003; Ballestri et al., 2007; Dumas et al., 
2015). In veterinary medicine, HVS is frequent feature 
in patients with monoclonal gammopathies (Giraudel 
et al., 2002). PE has been used in veterinary medicine 
to treat HVS (Matus et al., 1983; Wahlin et al., 1984; 
Giraudel et al., 2002; Vail, 2007; Borgatti, 2010), but 
no data are available regarding the use of DFPP.
The present study reported for the first time the use of 
DFPP to reduce clinical signs of HVS in a dog with 
multiple myeloma.
Case Details
A 12 year old, 38 kg (83.12 lb), mix-breed, intact male dog 
presented with a 20-day history of clinical signs consistent 
with HVS. The dog had been diagnosed with multiple 
myeloma 17 months before, based on bone marrow 
plasmocytosis and serum monoclonal gammopathy. 
Initial therapy had included melphalan (Alkeran®, 
GlaxoSmithKline) at 0.05 mg/kg/day (0.02 mg/lb/day) 
and prednisolone (Deltacortene®, Bruno Farmaceutici) 
at 1 mg/kg/day (0.45 mg/lb/day). The patient had shown 
significant clinical improvement for 15 months on this 
treatment protocol. At time of presentation the patient 
was no longer responsive towards medical therapy 
and showed signs of HVS. At clinical examination the 
dog showed weight loss (1.5 kg (3.5 lb) within one 
month), severe panting and weakness and unilateral 
blindness as a consequence of a retinal hemorrhage. 
The haematological and biochemistry analysis showed 
a moderate non-regenerative anemia, with lymphopenia, 
monocytopenia, eosinopenia and thrombocytopenia, as 
well as a marked increase in serum total protein. Serum 
electrophoresis revealed an increase in gamma globulins, 
and a reduction in albumin, alpha-1 globulins, and beta 
globulins (Table 1). HVS was diagnosed on the basis of 
the clinical and laboratory signs.
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Abstract
A 12 year old, 38 kg, mix-breed, intact male dog presented with a 20 day history of clinical signs consistent with 
hyperviscosity syndrome secondary to multiple myeloma. The dog received three double filtration plasmapheresis 
treatments on day 0, 7 and 22 after presentation. A significant (p<0.05) reduction in serum total protein, alpha-2 and 
gamma globulins was found following each treatment. These reductions were accompanied by a complete resolution, 
although temporary, of the clinical signs of hyperviscosity syndrome. The present study reported for the first time the 
use of double filtration plasmapheresis to reduce clinical signs of hyperviscosity syndrome in a dog with multiple 
myeloma.
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Chest radiographs and abdominal ultrasound at 
presentation were unremarkable. With the owner’s 
informed consent, the dog was anesthetized and a 12 Fr, 
15 cm dual lumen central venous catheter (Haemocath® 
Signo V 1215, BBraun) was placed in the right 
jugular and advanced into the cranial vena cava via 
the Seldingher technique. A CRRT machine (Diapact® 
CRRT System BBraun, Melsunghen) was used in DFPP 
modality. The extracorporeal blood circuit volume 
was 150 ml. A 0.2 m2 polyethylene plasma separator 
(Plasmaflo™ OP-02, ©Asahi Kasei Kuraray Medical Co., 
Ltd), with a 25 ml of priming volume and a maximum 
pore size of 0.3 μm, was used for separating plasma. 
A 2 m2 ethylene vinyl alcohol copolymer plasma filter 
(Cascadeflo™ EC-50, ©Asahi Kasei Kuraray Medical 
Co., Ltd), with 110 ml of priming volume, was used 
for membrane filtration. The total plasma volume of 
the patient was estimated to be approximately 1900 ml 
(Wellman et al., 2012). Using guidelines established 
in human medicine, blood flow and plasma flow were 
set at 70 ml/min and 20 ml/min respectively and the 
treatment time was set at 2 hours, to obtain an estimated 
macromolecule reduction ratio (MRR) of 70%. Heparin 
was administered as an intravenous bolus at 100 UI/kg 
(45.3 UI/lb) five minutes before starting the procedure, 
then as a continuous rate intravenous infusion at 
50 UI/kg/h (22.6 UI/lb). Anticoagulation was monitored 
and adjusted based on activated clotting time (ACT) 
obtained every 30 minutes (Ismail et al., 2007).
The dog received treatments on day 0, 7 and 21 following 
presentation. No complications were encountered 
during the treatments, with the exception of poor 
catheter performance during the third treatment, that 
necessitated reversal of the arterial and venous lines. 
Pre-treatment blood samples were collected 10 minutes 
before the start of the procedure. Post-treatment blood 
samples were collected 15 seconds after the end of 
the procedure at a standard blood flow of 50 ml/min. 
The pre-treatment and post-treatment values of each 
plasmapheresis session (Table 2) were compared 
using a two-way ANOVA (p<0.05) and using standard 
statistics software (Fig. 1, Fig. 2, Fig. 3 and Fig. 4).
During the first treatment (Day 0) a macromolecular 
reduction ratio (MRR) of 33.9% was obtained, while 
in the second (Day 7) and in the third (Day 21) 
treatment a MRR of 43.4% and 28.8% were obtained 
respectively. Associated with the significant 
reduction of the plasma protein (Table 2) was an 
almost complete resolution of the clinical signs. 
The dog developed catheter complications two days 
after the last treatment and the owners decided not to 
replace it. The patient died within 25 days of the last 
plasmapheresis.
Fig. 1. Serum concentration of total protein before and after 
each plasmapheresis treatment. First treatment (T:1), second 
treatment (T:2), third treatment (T:3). Two-way ANOVA 
showed a significant reduction of total protein in in the post-
treatment sample (p=0.007).
Fig. 2. Serum concentration of alpha-2 globulins before and 
after each plasmapheresis treatment. First treatment (T:1), 
second treatment (T:2), third treatment (T:3). Two-way 
ANOVA showed a significant reduction of alpha-2 globulins 
in the post-treatment sample (p=0.01).
Table 1. Haematological and biochemical abnormalities.
Parameters Value Reference range
RBC 3.36 5.65-8.87 (M/μL)
Hct 20.9 37.3-61.7 (%)
Hgb 7.4 13.1-20.5 (g/dL)
Reticulocytes 7.5 10.0-110.0 (K/μL)
WBC 4.39 5.05-16.76 (K/μL)
Lymphocytes 0.45 1.05-5.10 (K/μL)
Monocytes 0.15 0.16-1.12 (K/μL)
Eosinophils 0.05 0.06-1.23 (K/μL)
PLT 24 148-484 (K/μL)
Total protein 11.8 5.5-7.7 (g/dL)
Albumin 2.63 2.7-4.0 (g/dL)
Alpha-1 globulins (g/dL) 0.25 0.3-0.4 (g/dL)
Alpha-2 globulins (g/dL) 1.23 0.6-1.4 (g/dL)
Beta-globulins (g/dL) 0.55 0.7-2.4 (g/dL)
Gamma globulins (g/dL) 7.14 0.4-0.9 (g/dL)
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Discussion
HVS is a complication of multiple myeloma, occurring 
in approximately 20% of dogs affected by the disease 
(Borgatti, 2010). In one study (Giraudel et al., 2002), 
signs of HVS were observed in 23% of the dogs with 
a monoclonal gammopathies in general. The clinical 
presentation of HVS is variable, but typically includes 
one or more of the following: bleeding diathesis, 
neurologic signs (such as seizures, depression, coma), 
congestive heart failure, renal failure, and ophthalmic 
abnormalities, including tortuous and dilated retinal 
vessels, retinal hemorrhages, and retinal detachment, 
sludging of blood within small vessels, and impaired 
delivery of nutrients and oxygen to tissues (Vail, 2007; 
Borgatti, 2010).
HVS is a primary indication for the use of therapeutic 
plasmapheresis in humans (Wahlin et al., 1984; Mehta 
and Singhal, 2003; Zarcovic and Kwaan, 2003) but 
also in companion animals (Vail, 2007; Boyle et al., 
2011). Therapeutic apheresis is an extracorporeal 
blood purification technique, designed for the removal 
of either plasma (plasmapheresis) or cellular blood 
components (cytopheresis) (Zarcovic and Kwaan, 
2003). Plasmapheresis can be performed using either 
a centrifugal or a membrane filtration technique. In 
humans, centrifugal plasmapheresis is the primary 
modality in North America to separate the plasma from 
the other blood components (Drew, 2002; Zarcovic and 
Kwaan, 2003), while membrane plasma separation is 
more common in Europe and Japan.
The membrane filtration technique consists of 
separation of plasma from whole blood through a 
plasma separator and then removal of components 
of plasma through a plasma filter or plasma adsorber 
(Siami and Siami, 1999; Lyu et al., 2002). The treated 
plasma is then mixed with cellular blood components 
and infused back into the patient’s circulation, without 
the need for replacement fluid (Lyu et al., 2002).
In the present study, post-treatment samples (Table 2) 
showed a significant reduction of the serum concentrations 
of both alpha-2 (Fig. 2) and gamma globulins (Fig. 3) 
(p=0.01 and p=0.008), indicating a significant efficacy of 
DFPP in reducing both acute and chronic inflammatory 
compounds. In the immediate post apheresis period 
for each treatment, the patient experienced a complete 
remission of clinical signs of HVS. This finding was in 
Fig. 3. Serum concentration of gamma globulins before and 
after each plasmapheresis treatment. First treatment (T:1), 
second treatment (T:2), third treatment (T:3). Two-way 
ANOVA showed a significant reduction of gamma globulins 
in the post-treatment sample (p=0.008).
Fig. 4. Serum concentration of albumin before and after 
each plasmapheresis treatment. First treatment (T:1), second 
treatment (T:2), third treatment (T:3). Two-way ANOVA 
showed a significant reduction of the albumin concentration 
in the post-treatment sample (p=0.04).
Table 2. Pre-treatment and post-treatment values and statistic value (p-value) of total protein, albumin, alpha 1 globulins, alpha 2 
globulins, beta globulins and gamma globulins for each plasmapheresis session.
Parameters Day 0 Day 7 Day 21
Pre Post p value Pre Post p value Pre Post p value
Total protein (g/dL) 11.8 7.8* (p=0.007) 10.6 6.0* (p=0.007) 11.8 8.4* (p=0.007)
Albumin (g/dL) 2.63 1.81* (p=0.04) 2.47 1.43* (p=0.04) 2.63 2.13* (p=0.04)
Alpha-1 globulins (g/dL) 0.25 0.26 0.23 0.19 0.25 0.17
Alpha-2 globulins (g/dL) 1.23 0.57* (p=0.01) 1.23 0.61* (p=0.04) 1.23 0.78* (p=0.04)
Beta globulins (g/dL) 0.55 0.71 0.46 0.47 0.55 0.28
Gamma globulins (g/dL) 7.14 4.42* (p=0.008) 6.11 3.29* (p=0.008) 7.14 5.05* (p=0.008)
*Significant difference between the pre- and the post-treatment concentration. 
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agreement with a significant reduction of post-treatment 
serum total protein (p=0.007) compared to pre-treatment 
values (Fig. 1). The clinical significance of the present 
finding is even more important if the actual MRR is 
considered. Although the average MRR of the three 
treatments (35.4%) was lower than expected (70%), 
a complete resolution of clinical signs of HVS was 
achieved. The largest MRR occurs with removal of the 
first volume of plasma. MRR becomes progressively less 
effective as subsequent plasma volumes are processed. 
For this reason one and at most two plasma volume 
equivalents are generally treated during a plasmapheresis 
session (Ismail et al., 2007).
The length of time between two subsequent treatments 
was not the same and this element may have affected 
the relative MRR. The intravascular rebound of 
macromolecules is driven initially by diffusion of 
solutes from the extravascular to the intravascular 
space and then by endogenous synthesis. Finally, 
at the beginning of the third treatment a dysfunction 
of the arterial port of the venous catheter occurred, 
making the inversion of the ports necessary in order to 
maintain the scheduled blood flow. This fact may have 
contributed to reduce the efficacy of the treatment by 
increasing recirculation.
Cascadeflo™EC-50 is considered the plasma filter 
of choice for LDL-C removal (Molecular Weight 
approx. 2.400.000) in humans (Fernández-Fuertes 
et al., 2010) with a very high sieving coefficient (0.8) 
for IgG and total protein (Fig. 2). Compared to other 
available plasma filters (EC-20, EC-30 and EC-40), 
Cascadeflo™EC-50 showed a significantly lower 
in vitro and in vivo removal of albumin. The use of 
Cascadeflo™EC-50 has been associated with a loss of 
only 10% of albumin. Therefore, the use of replacement 
solution is generally not necessary (Fernández-Fuertes 
et al., 2010; Lumlertgul et al., 2013). In the present 
case, the post-treatment concentrations of serum 
albumin were only mildly reduced (Fig. 4) and not 
associated with clinical signs of hypoalbuminemia. 
As a consequence, we opted not to give the patient 
replacement solution. Comparing to PE technique, 
double filtration shows some advantages (Lyu et al., 
2002; Kasuya et al., 2013). The use of a plasma filter, 
instead to remove all patient’s plasma, allows for a 
more selective removal of the targeted compounds, 
with minimal loss of non-pathogenic substances and 
albumin. The main advantage of DFPP is to infuse 
the patient back with its own purified plasma, with 
minimal or no need of reinfusion solutions (Lyu et al., 
2002; Yeh et al., 2006), thus avoiding the high costs 
associated with plasma or albumin supplementation 
and limiting the depletion of the coagulation factors 
and other plasma compounds, that are removed when 
the PE is used. Additionally, the DFPP avoids potential 
complications such as risk of infection or protein 
allergy, that may result from the exogenous plasma/
albumin transfusion (Lyu et al., 2002; Ismail et al., 
2007; Kasuya et al., 2013). Moreover, the treatment 
requires a very short time (about two hours) and can be 
performed by using heparin as an anticoagulant, instead 
of citrate (Ismail et al., 2007). On the basis of our first 
clinical experience, DFPP seemed to have a good 
efficacy to remove the excess of globulins and total 
protein, as previously reported in human medicine. In 
veterinary medicine, the use of PE technique has been 
reported in association with chemotherapy to treat HVS 
due to multiple myeloma (Matus et al., 1983; Wahlin 
et al., 1984; Giraudel et al., 2002; Borgatti, 2010) but 
no data regarding the use of DFPP were available. The 
main limitation to the use of DFPP may be represented 
by the large volume of the extracorporeal circuit 
(285 ml), that may significantly limit the use of DFPP 
in small size patients. At present there are no available 
data about the potentially application of this technique 
in dogs with low weight, but the use of DFPP with 
extracorporeal high volume (410 ml) is reported in 
children (Fernández-Fuertes et al., 2010). The present 
patient did not show any remarkable complications 
(hypotension, bleeding, infection, allergy reaction) 
and all clinical signs of HVS resolved completely in 
the inter-treatment interval of time. On the basis of 
these first clinical acquisitions, DFPP seems to be an 
interesting and promising technique, that deserves 
further investigations in the veterinary patient.
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